U.S. Markets close in 24 mins

Exelixis Inc (EXEL) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Exelixis Inc (EXEL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company. Exelixis Inc has a market cap of $6.43 billion; its shares were traded at around $21.52 with a P/E ratio of 9.73 and P/S ratio of 9.04.


For the last quarter Exelixis Inc reported a revenue of $228.6 million, compared with the revenue of $120.1 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $853.8 million, an increase of 88.7% from last year. For the last five years Exelixis Inc had an average revenue growth rate of 115.3% a year.

The reported diluted earnings per share was $2.21 for the year, compared with the loss per share of $1.34 in the previous year. The Exelixis Inc enjoyed an operating margin of 51.4%, compared with the operating margin of 36.66% a year before. The 10-year historical median operating margin of Exelixis Inc is -115.01%. The profitability rank of the company is 6 (out of 10).

At the current stock price of $21.52, Exelixis Inc is traded at 11.4% discount to its historical median P/S valuation band of $24.29. The P/S ratio of the stock is 9.04, while the historical median P/S ratio is 10.22. The stock lost 26.8% during the past 12 months.

CEO Recent Trades:

  • President and CEO Michael Morrissey sold 40,000 shares of EXEL stock on 02/14/2019 at the average price of $22.39. The price of the stock has decreased by 3.89% since.
  • President and CEO Michael Morrissey sold 40,000 shares of EXEL stock on 01/30/2019 at the average price of $23.12. The price of the stock has decreased by 6.92% since.

Directors and Officers Recent Trades:

  • Director Charles Cohen sold 248,180 shares of EXEL stock on 02/19/2019 at the average price of $22.14. The price of the stock has decreased by 2.8% since.
  • Pres, Prod Dev & Med Aff & CMO Gisela Schwab sold 123,000 shares of EXEL stock on 02/15/2019 at the average price of $21.76. The price of the stock has decreased by 1.1% since.
  • Director Carl B Feldbaum sold 50,500 shares of EXEL stock on 02/14/2019 at the average price of $22.03. The price of the stock has decreased by 2.32% since.
  • Sr. Vice President, Commercial Patrick J. Haley sold 1,000 shares of EXEL stock on 02/11/2019 at the average price of $21.3. The price of the stock has increased by 1.03% since.
  • Director George A Scangos sold 40,000 shares of EXEL stock on 02/01/2019 at the average price of $23.53. The price of the stock has decreased by 8.54% since.

For the complete 20-year historical financial data of EXEL, click here.

This article first appeared on GuruFocus.